Mobactam, a new synthetic monobactam was administered to 27 patients with severe infections. Clinical evaluations were made after monotherapy according to UTI criteria, as excellent in 5 patients, moderate in 14 patients and poor in 8 patients.
Overall
clinical effectiveness rate was 70.4%. For those who did not completely cured with mobactam monotherapy (22 patients), addition of ceftriaxone brought 18 more patients including 11 cure patients in clinical effectiveness group.
Antibiotic sensitivity tests was performed using 96 gram-negative strains isolated from patients in intensive care units. Mobactam has shown sensitivity of 79% to Pseudomonas spp. which was comparable to amikacin and superior to other available
antibiotics tested. For Klebsiella pneumoniae, mobactam was the most effective and the least in prevalence of resistant strains. Overall, mobactam was an effective antibiotic for eradicating gram-negative bacilli such as Pseudomonas spp.,
Klebsiella
spp., Enterobacter spp., and Proteus spp.
Based on this results, we conclude that mobactam can be safely used as a primary antibiotic in patients with severe infections.
|